The company's recent approval in China for its GLP-1 drug is a significant development, opening access to a massive market where patents for GLP-1s are set to expire as early as 2026
When interpreting any platform's weight loss statistics, it helps to consider that self-reported data from users who consistently track their weight may represent a more motivated and adherent subset of overall members
If you experience symptoms that concern you after starting a compounded GLP-1 medication - severe nausea, vomiting, abdominal pain, or other unexpected reactions - contact your assigned clinical provider through Omzo's care platform first
The following table breaks down key characteristics of various GLP-1 RAs, including Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Trulicity, Saxenda, and Victoza, to give a clearer picture of their differences: This table elucidates the Ozempic vs Mounjaro debate, showing Mounjaros unique position with very high efficacy in both weight loss and blood sugar control
Ozempic is not indicated for patients with type 1 diabetes or for the treatment of diabetic ketoacidosis
